Top Page
Sisram Medical Ltd.
(1696)
Sisram Medical Ltd. (1696) vs. iShares MSCI Hong Kong ETF (EWH)
Sisram Medical Ltd. Business Overview & Revenue Model
Sisram Medical Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 349.11M | 359.29M | 354.48M | 294.29M | 162.09M |
| Gross Profit | 216.68M | 219.53M | 202.23M | 166.86M | 90.30M |
| EBITDA | 38.91M | 53.43M | 58.38M | 55.96M | 28.19M |
| Net Income | 25.13M | 31.50M | 40.17M | 31.25M | 13.34M |
Balance Sheet | |||||
| Total Assets | 627.26M | 613.50M | 555.60M | 530.13M | 431.81M |
| Cash, Cash Equivalents and Short-Term Investments | 71.98M | 70.60M | 81.41M | 152.92M | 116.37M |
| Total Debt | 43.20M | 44.68M | 41.34M | 41.62M | 37.06M |
| Total Liabilities | 142.47M | 143.98M | 123.38M | 126.51M | 99.92M |
| Stockholders Equity | 464.03M | 452.31M | 430.87M | 402.18M | 331.89M |
Cash Flow | |||||
| Free Cash Flow | 30.38M | 35.37M | -42.28M | 29.41M | 16.46M |
| Operating Cash Flow | 33.08M | 43.94M | 22.04M | 32.38M | 25.74M |
| Investing Cash Flow | -6.59M | -32.99M | -52.11M | -46.77M | -33.51M |
| Financing Cash Flow | -16.11M | -20.97M | -17.85M | 55.78M | -12.21M |
Sisram Medical Ltd. Technical Analysis
Sisram Medical Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$2.75B | 14.02 | 5.49% | 2.29% | -3.16% | -20.69% | |
51 Neutral | $7.95B | -0.40 | -42.50% | 2.21% | 22.29% | -1.85% | |
| ― | €558.27M | ― | -11.20% | ― | ― | ― | |
| ― | €466.05M | 34.43 | 7.44% | ― | ― | ― | |
73 Outperform | HK$8.55B | 111.24 | 1.98% | ― | 3.42% | -70.82% | |
62 Neutral | HK$6.66B | 20.81 | 11.24% | 1.22% | 25.18% | 55.79% | |
| ― | HK$3.60B | ― | -1.39% | ― | ― | ― |
Sisram Medical Ltd. Corporate Events
Sisram Medical Ltd. has announced a final cash dividend of HKD 0.126 per share for the fiscal year ending December 31, 2024. The dividend will be subject to a 20% withholding tax as per Israeli Tax Ordinance, with the payment date set for September 9, 2025. Shareholders have the option to apply for a reduced tax rate under applicable tax treaties, although no such treaty exists between Israel and Hong Kong. This announcement reflects the company’s commitment to returning value to its shareholders while navigating the complexities of international tax regulations.
Sisram Medical Ltd has announced a final dividend of HK$0.126 per share for the year ending December 31, 2024, to be paid on or around September 9, 2025. Shareholders will be subject to a 20% withholding tax on the dividend, with provisions for reduced rates under applicable tax treaties, although no such treaty exists with Hong Kong.
Sisram Medical Ltd has announced that its board of directors will meet on August 20, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the declaration of an interim dividend, which could impact the company’s financial distribution to shareholders.
Sisram Medical Ltd announced that the commercialization of its product, DAXXIFY® (DaxibotulinumtoxinA-lanm), in Mainland China is progressing steadily. The company is actively working on regulatory filings, market access, and building a professional team to support the product’s launch, expressing strong confidence in its market potential.
Sisram Medical Ltd has announced the launch of Universkin, an AI-powered personalized medical-grade skincare system, in the U.S. market through its subsidiary Alma Lasers Ltd. This product utilizes AI-assisted software to provide tailored skincare formulations, marking a significant step in personalized skincare treatment. The company anticipates that this launch will enhance its product portfolio, boost market competitiveness, and serve as a new revenue driver, setting the stage for a global rollout.
Sisram Medical Ltd has announced changes in the composition of its board committees, effective June 24, 2025. These changes involve the appointment of new members and chairpersons for the audit, remuneration, and nomination committees, potentially impacting the company’s governance and strategic direction.
Sisram Medical Ltd has announced the updated list of its board of directors and their roles, effective June 24, 2025. This update in leadership structure, including executive, non-executive, and independent non-executive directors, may influence the company’s strategic direction and governance, potentially impacting its stakeholders and market positioning.
Sisram Medical Ltd has updated the terms of reference for its Nomination Committee, which was originally established in 2017. The committee will consist of at least three members, primarily independent non-executive directors, and will ensure diversity with at least one director of a different gender. This move is likely to strengthen the company’s governance structure, potentially enhancing its industry positioning and stakeholder confidence.
Sisram Medical Ltd held its Annual General Meeting on June 24, 2025, where all proposed resolutions were passed. Key resolutions included the re-election of directors and the reappointment of auditors, as well as mandates for share buybacks and issuance. This demonstrates strong shareholder support and positions the company for strategic flexibility in its operations.
Sisram Medical Ltd has entered into a Supply Framework Agreement with Fosun Wanbang (Jiangsu) to supply botulinum toxin type A for injection, known as DAXXIFY®, in Mainland China. This agreement aligns with Sisram’s business model and is expected to generate additional revenue, enhancing its market position. The collaboration with Fosun Wanbang, a qualified institution for distributing medical toxins in China, is strategically beneficial due to its independence from competitors and nationwide distribution capabilities. This partnership supports Sisram’s long-term commercial planning and operational efficiency.
Sisram Medical Ltd has announced its upcoming annual general meeting scheduled for June 24, 2025, in Hong Kong. Key agenda items include the re-election of several directors and the re-appointment of Ernst & Young as auditors. Additionally, the company seeks approval for mandates to buy back shares and issue additional shares, which could impact its market operations and shareholder value.